Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.240 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Curious about the stocks that are showing activity after the closing bell on Thursday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
From AbCellera Biologics Inc.
Via Business Wire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
Via The Motley Fool
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q1 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript
ABCL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.